Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28116379 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL19657171 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL14450224 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL27370160 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983910 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL30616797 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5953088 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL20466819 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL20268 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5709929 | 0.99 | DNMT1 (0.62) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649153-A1 | MODIFIED MULTI-SEGMENTED ANTISENSE OLIGONUCLEOTIDES FOR USE | Ausperbio Therapeutics Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250215430-A1 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | AUSPERBIO THERAPEUTICS INC. | 2025-07-03 | — | — | US | claimed |
| EP-4463550-A2 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | Ausperbio Therapeutics Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240368602-A1 | OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES | AUSPERBIO THERAPEUTICS INC. | 2024-11-07 | — | — | US | claimed |
| WO-2024149282-A1 | MODIFIED MULTI-SEGMENTED ANTISENSE OLIGONUCLEOTIDES FOR USE | AUSPERBIO THERAPEUTICS INC. (US) | 2024-07-18 | — | — | WO | claimed |
| EP-3554255-B1 | COMPOSITIONS AND METHODS THAT MODULATE CHOLESTEROL IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| WO-2023131926-A2 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | AUSPER BIOPHARMA CO., LTD. (CN) | 2023-07-13 | — | — | WO | claimed |
| WO-2023131098-A2 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | AUSPER BIOPHARMA CO., LTD. (CN) | 2023-07-13 | — | — | WO | claimed |
| US-20230212582-A1 | COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2023-07-06 | — | — | US | claimed |
| EP-4139459-A2 | COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDES (ASO) AND METHODS OF USING THE SAME | Nogra Pharma Limited (IE) | 2023-03-01 | — | — | EP | claimed |
| US-20070066551-A1 | Aptamer medicinal chemistry | ARCHEMIX CORP. | 2007-03-22 | — | — | US | claimed |
| WO-2006029258-A2 | APTAMER MEDICINAL CHEMISTRY | ARCHEMIX CORP. (US) | 2006-03-16 | — | — | WO | claimed |
| US-6111094-A | OLIGONUCLEOTIDE WITH AT LEAST ONE 2' MODIFICATION; FOR MODULATION OF HUMAN INTRACELLULAR ADHESION MOLECULE-1; ANTIINFLAMMATORY/ANTICARCINOGENIC/ ANTIMETASTASIS AGENTS; ANTIARTHRITIC AGENTS; TREATMENT OF SKIN DISORDERS | ISIS PHARMACEUTICALS INC. (US) | 2000-08-29 | — | — | US | claimed |
| EP-0923596-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-06-23 | — | — | EP | claimed |
| US-5888777-A | Process for the complete removal of protective groups on nucleoside diphosphate and triphosphate sugars with acetylesterase | NOVARTIS AG (CH) | 1999-03-30 | — | — | US | claimed |
| US-5763208-A | Oligonucleotides and their analogs capable of passive cell membrane permeation | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | claimed |
| WO-1998004575-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| EP-0801684-A1 | PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS | Novartis AG (CH) | 1997-10-22 | — | — | EP | claimed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | claimed |
| WO-1996024683-A1 | PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS | NOVARTIS AG (CH) | 1996-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368602-A1 | OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES | TYMS, TYMP, NSUN2 | DNMT1 591/4885ADRB1 4301/4885DNMT3B 459/4885 |
| US-20250215430-A1 | MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION | HAVCR2, WNT1, SRRT | DNMT1 435/4885ADRB1 3338/4885DNMT3B 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.